


# HEMATOPATHOLOGY

2017/2018  
2nd semester

# MYELOID

## NORMAL HAEMOPOIESIS

# LYMPHOID




ACUTE

Immature cells - blasts

CHRONIC


mature cells

*Classification of  
bone marrow  
neoplasms*




MYELOID

LYMPHOID



# Classification of hematologic diseases (WHO)



Lymphoma – Leukemia  
cannot be separated unambiguously

# Leukemia → derives from the bone marrow

Totally immature **blast cells (acute)** or  
more matured **progenitors (chronic)**

\* replace normal haematopoiesis

\* after a while they get into circulation

## Bone marrow

- Blast < 5% → normal
- **Blast > 20%** → acute leukemia

SYMPTOMS: **Rapid** development

In children days / 1-2 weeks


**Slow** development




see: ACUTE leukemia



see: CHRONIC leukemia



NORMAL BONE MARROW



RED BONE MARROW IN ADULTS

# Leukemia

## GENERAL SYMPTOMS:

### BONE MARROW FAILURE

: Tumor cells replace normal hematopoiesis

Red blood cell ↓



**ANAEMIA**



Fatigue

Thrombocyte ↓



**THROMBOCYTOPENIA**



Hemorrhage; DIC

Neutrophil ↓



**NEUTROPENIA**



Infections; Fever

Blast ↑



**LEUKOCYTOSIS**



Leukostasis

Metabolism ↑



**SWEATS  
FATIGUE**

### ORGAN INFILTRATION

: Tumor cell infiltration of different organs

Spleen



**SPLENOMEGALY**

Liver



**HEPATOMEGALY**

Lymph node (rarely affected)



**LYMPHADENOMEGALY**

Gingiva



**GINGIVAHYPERPLASIA**

Bone marrow



**BONE PAIN**



# Acute leukemia – Separation

## LYMPHOID



**TdT** :DNA polymerase

✓ lymphoblast

✗ lymphocyte

✗ myeloblast

## Nuclear staining

**N.B.: Not 100% specificity**

TdT can be expressed by any blast cell, but it is more characteristic in lymphoid cells

MPO do not present in all AML forms



## MYELOID / MONOCYTAER

**MPO** :myeloperoxidase

**Auer rod (HE)** –  
crystallized MPO

**NSE** :non-specific esterase

## Cytoplasmic staining





# Acute lymphoid leukemia

**80% of childhood leukemias are ALL**

## *Useful information:*

30% of acute leukemias are ALL, 70% are AML

75% of ALL present under the age of 6

80% of childhood leukemias are ALL

85% of ALLs are B-ALL, 15% are T-ALL

Recovery rate in children is 80%  
in adults is 50%

**B-ALL (85%)** : markers: Ig, CD10, CD19, CD20

Currently used WHO classification depends on genetic alterations

pl.: t(12;21) – ETV6-RUNX1; good prognosis; usually in children  
t(9;22) = Ph<sup>+</sup> – BCR-ABL1; poor prognosis; usually in adults

**T-ALL (15%)** : markers: CD3, CD4, CD8

T-Lymphoblastic Leukemia/Lymphoma

Teenagers; Thymus/mediastinal widening

Formerly: FAB classification

based on cytomorphology

no prognostic or therapeutic consequence

not used anymore

# Acute myeloid leukemia

Median age at the time of diagnosis: 68 y.o.

## WHO classification (not obligatory to learn)

- **AML with recurrent genetic abnormalities**
  - AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
  - AML with inv(16)(p13.1q22) or t(16;16); CBEB-MYH11
  - Acute promyelocytic leukemia (APL) with t(15;17); PML-RARA
  - AML with t(9;11); MLLT3-MLL
  - AML with t(6;9); DEK-NUP214
  - AML with inv(3) or t(3;3); RPN1-EVI1
  - AML (megakaryoblastic) with t(1;22); RBM15-MKL1
  - Provisional entity: AML with mutated NPM1
  - Provisional entity: AML with mutated CEBPA
- **AML with myelodysplasia-related change**
- **Therapy-related myeloid neoplasms**
- **AML NOS (not otherwise specified):**
- **Myeloid sarcoma**
- **Myeloid proliferations related to Down syndrome**
- **Blastic plasmacytoid dendritic cell neoplasm**

## Useful information:

- 30% of acute leukemias are ALL, 70% are AML
- AML most commonly: between the age of 50 and 70
- Cytomorphologic classification is also changed by **cytogenetic classification (FAB vs WHO)**
- Genetic aberrations predict prognosis:  
good – intermediate – poor prognosis

Poor prognostic factors:

Older age

FLT3 mutation (tyrosine kinase); del chr 5/7

Association with MDS or therapy (chemo/radio)

## FAB classification (see. slide 2-3) (not obligatory to learn)

FAB	Name	Adult patients (%)
M0	Min. differentiated acute myeloblastic leukemia	5%
M1	Acute myeloblastic leukemia without maturation	15%
M2	Acute myeloblastic leukemia with maturation	25%
M3	Acute promyelocytic leukemia	10%
M4	Acute myelomonocytic leukemia	20%
M4eos	Acute myelomonocytic leukemia with bm. eosinophilia	5%
M5	Acute monocytic leukemia	10%
M6	Acute erythroid leukemia	5%
M7	Acute megakaryocytic leukemia	5%

# Acute myeloid leukemia

**Acute promyelocytic leukemia (APL)** tumor cells with Auer rods!

Success story of leukemia therapy

Worst prognosis until the '70s

→ rapid progression, fatal hemorrhages (DIC)

1977 – discovery of **t(15;17)** → PML-RARA fusion protein blocks differentiation

Th.: **ATRA** + chemo – induce the differentiation of promyelocytes, complete remission in 95%

**Acute monocytic leukemia**

Increased number of monoblasts


**Gingival hyperplasia!**

**Acute megakaryoblastic leukemia**

Associated with **Down syndrome** under the age of 5



# Chronic myeloproliferative diseases



Chronic megakaryocytic leukemia  
= idiopathic myelofibrosis (MF)

Essential thrombocytaemia (ET)

Polycythemia vera (PV)

Chronic neutrophil leukemia

Chronic eosinophil leukemia

Chronic basophil leukemia

CML

## Myelodysplasia

Ineffective hemopoiesis; pancytopenia

# Chronic myeloid leukemia (CML)

## Useful information:

- 20% of leukemia in adulthood are CML
- Median age at the time of diagnosis: 66 y.o.

**Median age at the time of diagnosis: 66 y.o.**

Low prevalence in younger age group, usually presents in a more aggressive form

## Specific genetic alteration

t(9;22) = Philadelphia chromosome → BCR-ABL fusion gene → BCR-ABL fusion protein  
presents in >90% of CML


- Intensive tyrosine-kinase activity
- The exact pathomechanism is unclear

## 3 phases:

1. Chronic (proliferation of more mature cells; 90% in asymptomatic)
2. Accelerated (further cytogenetic alterations)
3. Blast crisis (totally immature blast cells)

## Therapy (much better prognosis)

1. Imatinib (TKI)
2. Allogenic stem cell transplantation




# Chronic lymphoid leukemia (CLL)

## Useful information:

- Most common leukemia in adulthood
- Median age at the time of diagnosis: 72 y.o.

Clonal proliferation of nearly mature **B cells**

No or impaired Ig production



In the case of multiple lymph node involvement leukocytosis do not present:

**CLL = SLL (small lymphocytic lymphoma)**

+ It can transform to large B cell lymphoma (Richter transformation)

Cells are „fragile” → they crush when smear is made = **smudge cells**

Markers: CD19+, CD20+, **CD5+**, **CD23+**, CD38+, Zap70+,  $\gamma$  or  $\delta$  Ig chains; CD10-, cyclinD-



Pathogenesis: 13q14 del. → miR-15, miR-16 del. → **bcl2 overexpression** → anti-apoptosis

## Therapy

1. **Incurable** (elderly patients, bone marrow transplantation have high mortality rate)
2. The therapeutic goal is the asymptomatic condition, ex. biological therapies - rituximab (anti-CD20)
3. Indolent cases do not need any therapy



# Structure of normal lymph node





# Reactive lymphadenopathy

Benign, reversible, secondary enlargement of lymph nodes - hyperplasia

Morphological patterns (can refer to etiology)

## 1. Follicular hyperplasia

**B cell** response

Follicles with various size and shape

Enlarged germinal centers with prominent mantle zone


Small and large B-lymphocytes in the germinal center → centrocytes, centroblasts

Mitotic figures


Tingible body macrophages

No dominance of any cells type


Preserved subcapsular sinus



Normal Lymph Node



Reactive Follicular Hyperplasia



Reactive Node : Sinus Hyperplasia

## 2. Sinus histiocytosis

Dilated sinuses with groups of **histiocytes/macrophages**

# Reactive lymphadenopathy

Benign, reversible, secondary enlargement of lymph nodes - hyperplasia

Morphological patterns (can refer to etiology)

## 3. Diffuse paracortical hyperplasia

**T cell** response

Expansion of paracortical and interfollicular zones

Heterogenic cell population, no dominance of any cell type


Proliferation of HEV venules

## 4. Mixed


## 5. Acute lymphadenitis

The lymph node is infiltrated by **neutrophil granulocytes**


They present in the sinuses, in severe cases the whole lymph node is necrotic



Normal Lymph Node



Diffuse Hyperplasia





Mixed Hyperplasia




# Morphology of reactive lymphadenopathy – slide

- Enlarged lymph node, but it has normal shape (not roundish)
- Lots of transformed follicles = follicular hyperplasia



Normally stratified MZ

# Classification of hematologic diseases (WHO)



Lymphoma – Leukemia  
cannot be separated unambiguously



# Hodgkin lymphoma

Malignant, clonal, derives from B cells

Bimodal age distribution: Most common types:  
1st peak: age of 25-30 → nodular sclerosis  
2nd peak: age of 50-70 → mixed cellularity

## Etiology:

EBV

immunodeficiency (pl. HIV, chemo, transpl.)  
autoimmune diseases (pl. RA, sarcoidosis)

Male > Female

## Staging: I – IV

one or more lymphn. / extralymph organ  
below and/or above the diaphragm  
B symptoms +/-

5 year survival: 80-90%

## Clinical presentation:

Painless enlargement of lymph nodes

cervical lymphn. 60-70%

axillary lymphn. 20-30%

inguinal lymphn. 10-20%

mediastinal involvement

hepatosplenomegaly

B symptoms:

night sweats

weight loss

fever

Pel-Ebstein fever

Alcohol induced pain of lymph nodes

## Laboratory:

WBC count ↑/↓

eosinophilia, anemia, LDH ↑, vitD & Ca<sup>2+</sup> ↑

## Therapy:

chemoradiotherapy

the first successfully treated neoplasia

Lymphomas

85% – NHL

15% – HL

# Hodgkin lymphoma – Histology

## Histological classification (WHO)

### **CLASSIC Hodgkin lymphoma (CHL)**

#### **Nodular sclerosis (NSHL)**

most common subtype (> 60%); good prognosis

Localization: mostly mediastinal and cervical

#### **Mixed cellularity (MCHL)**

<30%; slightly poorer prognosis

Localization: mostly abdominal lymph. and spleen

#### **Lymphocyte-rich (LRHL)**

rare; good prognosis

Localization: mostly cervical and axillary

#### **Lymphocyte-depleted (LDHL)**

very rare (< 1%); worst prognosis

Localization: mostly below the diaphragm

### **NODULAR LYMPHOCYTE-PREDOMINANT (NLPHL)**

Rare (5%); best prognosis



## Morphology

= **Reed-Sternberg cell** (multinucleate)

= Hodgkin cell (uninucleate)

CD15+, CD30+, CD25+

CD45-, CD20-

**Inflammatory background:**

eosinophils, neutrophils, macrophages,  
lymphocytes, plasma cells, fibroblasts


Granuloma formation can occur

= **popcorn cell** (multilobulated nucleus)

CD15-, CD30-, CD20+    Ø RS cell

# Morphology of HL (nodular sclerosis) – slide







- Partial or complete involvement of lymph nodes
- Tumor cells with characteristic morphology! (ratio of tumor cells <10%)
- Accompanying sclerosis



Reactive cells (many eosinophils)



# Hodgkin lymphoma – Reed-Sternberg cells



<https://www.slideshare.net/Siddz0312/hodgkins-lymphoma-72629944>

[https://commons.wikimedia.org/wiki/File:Hodgkin\\_Disease,\\_Reed-Sternberg\\_Cell.jpg](https://commons.wikimedia.org/wiki/File:Hodgkin_Disease,_Reed-Sternberg_Cell.jpg)

# Non-Hodgkin lymphoma

**6th most common** neoplasm (85% of all lymphomas)

**Increasing incidence** worldwide

Incidence grows by age → peak: **>50 y.o.**

Risk factors:

Immunological (pl. autoimmune (pl. Hashimoto, Sjögren))

Infectious (pl. HTLV, EBV, HIV, HCV, H. pylori)

Genetic (pl. Klinefelter's sy, SCID)

Environmental (pl. smoking, pesticide, herbicide)

Malignant, **monoclonal** B or T cell proliferation

N.B.: reactive, non-tumorous lymphoid proliferation is polyclonal!

Presentation: **Nodal** and/or

→ lymph node

**Extranodal**

→ skin, GI system, CNS, testicle, ...

Growth patterns: **Follicular** or **Diffuse**

Survival (if not treated):

Low grade → 6-10 years

High grade → months

Poor prognostic markers:

Older age

Involved regions ↑

LDH ↑

β2-microglobulin ↑

# B cell NHL (85%)

😊 indolent  
☹ aggressive

**Precursor** B cell lymphoblastic  
leukemia/lymphoma

N.B.: acute lymphoblastic leukemia (ALL) = lymphoblastic lymphoma (LBL), same biological entities, different presentation

**Mature** B cell lymphoma

Follicular lymphoma 😊

Diffuse large B cell lymphoma ☹

Burkitt lymphoma ☹

MALT lymphoma 😊 / extranod. marg. zone lymphoma

Hairy cell leukemia 😊

Mantle cell lymphoma ☹

Lymphoplasmocytic lymphoma / Waldenström

B-CLL/SLL (small lymphocytic) lymphoma 😊

# T cell NHL (15%)

**Precursor** t cell lymphoblastic  
leukemia/lymphoma

**Mature** T cell lymphoma

Peripheral T cell lymphoma ☹

Adult T cell leukemia/lymphoma ☹

Mycosis fungoides 😊 / Sezary-sy ☹



# Follicular lymphoma

2nd most common NHL



**Most common indolent NHL**

Centrocyte origin

**t(14;18) *bcl-2*** gene translocation behind the Ig-promoter  
inhibition of apoptosis

Malignant follicles loose their polarity  
(no light-dark zones)

Absent or thin mantle zone





# Diffuse large B cell lymphoma (DLBCL)

- **Most common** NHL (20% OF NHLs)
- Most common **aggressive** NHL
- Development: de novo  
from other type of lymphomas by transformation (Richter transformation)
- Clinical presentation:  
painless enlargement of lymph nodes in one or more regions  
or extranodal mass  
→ stomach, Waldeyer ring, skin, soft tissue, brain, later bone marrow
- Rapid progression and fatal outcomes without therapy;  
60-80% complete remission with therapy



# Morphology of DLBCL - slide

- Diffuse growth pattern – the basic structure of the lymph node disappears
- centroblast, immunoblast-like tumor cells (ratio of tumor cells > 90%)
- Many mitotic figures - apoptoses (not in germinal centers but diffusely)





# Mantle cell lymphoma

Aggressive NHL

Mantle zone origin

**t(11;14)** translocation of **bcl-1/cyclinD1** gene behind the Ig-promoter  
stimulation of cell proliferation

# Burkitt lymphoma

**highly aggressive** NHL

Centroblast origin

**t(8;14)** translocation of **myc** gene behind  
the Ig-promoter  
stimulation of cell proliferation

Presentation:


endemic: extranodal → **jaw**

**Africa; EBV** association

sporadic: nodal → abdominal

less association with EBV

Characteristic histology: „ **starry sky pattern**”





# Marginal zone lymphoma

Indolent NHL



Marginal zone origin

Subtypes:

- Nodal
- Splenic
- **MALT-lymphoma (most common extranodal lymphoma)**
  - **Mucosa Associated Lymphoid Tissue**
  - Most common localization: **stomach**  
cause: chronic gastritis caused by **H. pylori**  
remission after eradication of H. pylori (in 55-75%)!
  - Transformation: **DLBCL**

# Stomach lymphoma morphology -slide

- Diffuse growth pattern in the stomach wall (ddg: diffuse type gastric cancer)
- Predominance of blasts, many mitotic figures = DLBCL



Infiltration of tumor cells in gastric wall

# T cell lymphomas

## Peripheral T cell lymphoma

Heterogenous group of diseases  
Mostly disseminated

## Adult T cell leukemia/lymphoma

Japan, Caribbean, Middle-Africa- endemic  
Associated with **HTLV-1**

## Mycosis fungoides

CD4 helper T cell origin  
Involvement of dermis and epidermis → Pautrier  
microabscesses  
Most common lymphoma of the skin  
Indolent  
Progression = **Sezary syndrome**




Figure 1: Clinical manifestations of mycosis fungoides—Image (A) shows typical early patch with erythema and mild scale; (B) shows a typical plaque, with raised, palpable borders, central clearing, and overlying scale; (C) shows a large tumor with necrosis and ulceration; and (D) shows generalized erythroderma. Reprinted with permission from Figure 1 in Smith B, Wilson L: *Oncology (Williston Park)* 17:1281-1288, 2003.[63]